Hatteras Ventures Partners

hatterasvp.com

VCMatch tracks Hatteras Ventures Partners as an investor focused on Biotech, Pharma, and Medtech companies, Series A and Series B rounds, Research Triangle (North Carolina, Usa), Southeast Us, and North America markets, and $44.5m to $80m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$44.5m to $80m

Stages

Series A, Series B, Series C

Focus Areas

Biotech, Pharma, Medtech

Geography

Research Triangle (North Carolina, USA), Southeast US, and North America

Investment Thesis

The firm focuses on advancing human medicine by building transformational healthcare companies that deliver measurable therapeutic or diagnostic benefits to patients and clinicians. They favor bold, high-impact science and technologies — “big, new ideas with breakthrough potential” — and take a hands-on, operational approach to de‑risking companies beyond providing capital.

Is Hatteras Ventures Partners right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Hatteras Ventures Partners is most relevant for founders raising Series A, Series B, and Series C rounds in Biotech, Pharma, Medtech, and Robotics, especially across Research Triangle (North Carolina, USA), Southeast US, and North America, with public check-size signals around $44.5m to $80m.

Focus statement

They invest in cutting‑edge healthcare companies across therapeutics, diagnostics and medical technologies (including platform and device companies), with an emphasis on clinical/translational stage programs that can materially improve patient outcomes and reduce treatment burden.

Value Add

Hands‑on operational support beyond capital: "Beyond capital, we assist with team recruitment, portfolio strategy, business development, regulatory and clinical planning, and much more. We roll up our sleeves to help our companies get it done."
Willingness to take calculated risks on breakthrough science: "We thrive on taking calculated risks. We invest in big, new ideas with breakthrough potential."
Patient‑centric, mission‑driven focus: "Every aspect of our work is oriented toward advancing human medicine. Our mission is to build transformational companies that benefit patients and the professionals who serve them."
Track record and scale: "With over 25 years and 100 companies under our belts, we have demonstrated we deliver value."
Regional leadership plus broad footprint: "Based in the Research Triangle, we are a leader in the Southeast while maintaining a robust North American investment footprint."
Preference for translational/academic‑origin technologies (e.g., portfolio companies spun out of universities such as Johns Hopkins shown in the Graybug case studies).